Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05680389
Status:
RECRUITING
Last Update Posted:
2023-01-11
First Post:
2022-12-26
Brief Title:
Antibiotics Against Amyloid Angiopathy
Sponsor:
Leiden University Medical Center
Organization:
Leiden University Medical Center
Study Overview
Official Title:
Placebo-controlled Randomized Double-blind Study of Minocycline for Sporadic and Hereditary Cerebral Amyloid Angiopathy
Status:
RECRUITING
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BATMAN
Brief Summary:
We will perform a randomized clinical trial with minocycline Minocycline is an antibiotic of the tetracycline family and known to modulate inflammation gelatinase activity and angiogenesis which we know are central mechanisms in CAA-pathology Our aim is to prove in a randomized clinical trial in a translational setting that minocycline treatment duration 3 months can decrease markers of neuroinflammation and the gelatinase pathway in the cerebrospinal fluid CSF of persons with D-CAA n30 and sporadic-CAA n30
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-004786-41 | EUDRACT_NUMBER | None | None |